Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 34Cyclophosphamide 29Mycophenolic Acid 25Cyclosporine 23Whole-Body Irradiation 22Tacrolimus 21Busulfan 18Antilymphocyte Serum 17Methotrexate 15Radiotherapy 14Flow Cytometry 13Filgrastim 13Etoposide 13Methylprednisolone 10Bortezomib 10Vorinostat 9Melphalan 9Therapeutics 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Lenalidomide 8Rituximab 7Gemcitabine 7Cord Blood Stem Cell Transplantation 6Bexarotene 6tanespimycin 5fludarabine 5aldesleukin 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × Aclarubicin × Dermatologic × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡